Introduction
Alzheimer's disease (AD) is the most common type of dementia in the United States [1] . Thus far, only symptomatic therapies are available, and there is a great need for disease-modifying therapies. The results of recent clinical trials have been disappointing, which has led to a growing interest in clinical trials design and interventions that target early stages of AD [2] such as targeting patients in asymptomatic/preclinical or mild cognitive impairment (MCI) stages. This shift to early stages of AD has underscored the need for validated biomarkers to identify patient populations who will benefit most from a potential therapeutic intervention.
One of the most widely studied biomarkers for AD is amyloid-b (Ab), thought to be an important protein in the pathogenic cascade of AD [3] . Cerebrospinal fluid (CSF) levels of Ab42 and Ab brain imaging measures have been extensively studied for use in clinical trials [4] . Although a blood-based biomarker would be even more widely applicable as it would be less invasive and less costly, most cross-sectional studies of plasma Ab levels have not been able to show differences between individuals at various stages of AD compared with those of controls [5, 6] . In addition, the utility of plasma Ab in earlier stages, such as MCI, is less clear [7, 8] .
To overcome these limitations, efforts to improve the utility of plasma Ab levels using an acute intervention to modulate plasma Ab have been investigated such as using insulin infusion in humans to change plasma and CSF Ab42 levels [9, 10] . More recently, oral glucose tolerance testing (OGTT) was used to compare AD patients with those with non-AD dementias [11] . However, it is still unknown whether a modulator of Ab plasma levels, such as OGTT, can be used to distinguish individuals in the earlier stages of AD from those with normal cognitive function. The goal of this study was to assess whether the degrees of change in plasma Ab40 and 42 levels are different in individuals with MCI/AD compared with those of cognitively normal controls (NC) in response to oral glucose loading.
Methods

Participants
This study was approved by the Johns Hopkins Institutional Review Board. Written informed consent was obtained from all subjects.
The study comprised 57 individuals, two with AD, 16 with MCI, and 39 with normal cognition (Table 1) . AD and MCI participants were combined in the analysis (exclusion of the AD subjects did not change the results). Subjects with AD met probable AD criteria by National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disorder and Related Disorder Association. MCI participants had a memory complaint corroborated by an informant, MCI documented in medical or research records, and a clinical dementia rating (CDR) of 0.5. Cognitively, NC had no reported memory impairments by history, a CDR of 0.0, and mini-mental state examination (MMSE) 26 or modified MMSE 86. Subjects were excluded if they had significant neurologic diseases, liver and renal dysfunction, or history of diabetes or treatment for diabetes.
Procedures
Subjects were asked to fast for 12 hours before a single early morning study visit. A 20-gauge peripheral intravenous was inserted, and blood was drawn at baseline before drinking a solution containing 75 g of glucose, then at 5, 10, 15, 30, 60, 90, and 120 minutes after drinking the solution.
Blood was collected in EDTA polypropylene tubes for plasma and centrifuged immediately after each collection at 542 relative centrifugal force for 15 minutes at 4 C. Plasma was separated from contact with cells immediately after centrifugation and stored at 280 C until analysis.
ELISA Ab40 and Ab42 levels were measured in plasma [6] using the MSD Multi-spot Abeta validated Triplex Assay (Meso Scale Discovery, Gaithersburg, MD, USA), by the Alzheimer's Disease Cooperative Study Biomarker Core using established standard operating procedures [7] . All samples were previously unthawed and run in duplicate. Internal standards were used to control for plate-to-plate variation.
Statistics
Baseline comparisons were made using two-sample t tests with Satterthwaite's approximation for degrees of freedom. Ab40 and 42 (D) values were calculated as the difference between the value at 10 minutes and the maximum value occurring before 10 minutes (at either 0 or 5 minutes). Logistic regression was performed to adjust for age and body mass index (BMI). All analyses were conducted using STATA (StataCorp LP, TX, USA).
Results
At baseline, no significant between-group differences were observed in age, sex, education, BMI, fasting glucose, baseline plasma Ab40 and 42 levels, and Ab42/40 ratios (Table 1) . We calculated the change (D) in plasma Ab as the higher level of plasma Ab from either 0 (baseline) or 5 minutes after ingestion of oral glucose solution to the 10-minute time-point after ingestion. Subjects with AD/MCI had significantly less change (D) in plasma Ab levels compared with that of controls in Fig. 1 . We also performed sensitivity and adjusted analyses. Nine subjects had well-documented history of depression. Excluding these individuals did not change the differences significantly, with subjects with AD/MCI having less change (D) in plasma Ab40 levels (23. 14 In separate logistic regressions of change (D) on diagnosis category, the unadjusted odds ratio (OR) for Ab40 (D) was 0.97 (95% confidence interval [CI], 0.94-0.99; P 5 .01) and for Ab42 (D) was 0.74 (95% CI, 0.57-0.96; P 5 .02), which means that there is 3% less risk of being in the MCI/AD group for every 1-pg/ mL difference in Ab40 (D) and 26% less risk for every 1 pg/mL difference in Ab42 (D). After adjusting for age and BMI, both ORs remained relatively unchanged and statistically significant; the OR for Ab40 (D) was 0.97 (95% CI, 0.94-0.99; P 5 .008) and for Ab42 (D) was 0.73 (95% CI, 0.56-0.95; P 5 .02).
Discussion
These findings suggest that individuals with MCI/AD have different degrees of change (D) in plasma Ab40 and 42 levels compared with those of cognitively NCs at the 10-minute time-point after an oral glucose load. Although OGTT has been used previously as a modulator of plasma Ab [11] , this study focused on comparing individuals with MCI or in the earlier stages of AD, whereas Takeda et al. [11] focused on comparing individuals with fairly advanced AD to those with non-AD dementias. In addition, our finding shows greater decline in plasma Ab40 and 42 levels from baseline to 10 minutes in cognitive NCs compared with that of MCI/AD individuals, not evident in the previous study, which examined plasma Ab levels over a 2-hour period but did not include the 5 or 10-minute time-points [11] .
At this time, the mechanism explaining these differences in the change in plasma Ab level is unclear. It is possible that OGTT modulated plasma Ab levels by increasing insulin secretion, as insulin is known to increase the level of plasma Ab42 in AD [10] . However, insulin level does not peak until 60-120 minutes after an OGTT [12] , whereas the change in plasma Ab levels occurred in the first 10 minutes after administration of glucose loading. Another possible mechanism involves glucagon-like protein-1 (GLP-1), a gastrointestinal hormone which is secreted in response to a meal or after an oral glucose challenge. GLP-1 may be involved in hepatic clearance of Ab. After production in intestinal cells, GLP-1 is transported to the liver via the portal vein [13] , also thought to be the primary route of clearance for Ab [14] . GLP-1 is also thought to play a role in amyloid precursor protein and Ab regulation [15] . Although the mechanism remains speculative, both insulin and GLP-1 levels after OGTT will be examined in the future studies to further delineate their roles.
In summary, our study suggests that oral glucose loading as a plasma Ab level modulator can "unmask" the differences between individuals with MCI/AD versus NCs. This method might be used to complement other existing biomarkers. For example, individuals with normallike drops in Ab levels might not be good candidates for further amyloid-oriented investigation via lumbar puncture for CSF collection or amyloid brain imaging in clinical trials or vice-versa. In addition, this method might differentiate those who are "cognitively normal" but already be in the preclinical stages of AD. In the latter case, normals with plasma Ab changes similar to the MCI/AD group would undergo more invasive amyloid testing. Both scenarios would reduce costs for AD clinical trials, but more importantly, spare individuals less likely to have AD pathology from undergoing unnecessary tests. This would be especially applicable in the developing world where most future AD cases are anticipated but where resources are limited. OGTT has a distinct advantage as a safe, noninvasive, cost-effective, and widely available biomarker that is already being used in clinical settings world-wide. 3. Future directions: OGTT combined with measures of plasma Ab40/42 might be used in the future to determine ideal candidates for interventions that target amyloid along with other existing biomarkers. In addition, due to its current world wide availability, lower cost, and noninvasive nature, this method has the potential to be widely disseminated to developing nations.
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